Chelsea Therapeutics to Host Conference Call to Discuss Second Quarter 2011 Results
20 juil. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., July 20, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release second quarter results for the period ended June 30, 2011 after...
Chelsea Therapeutics Announces Successful Completion of Northera QTc Study
20 juin 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., June 20, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced the successful completion of its dedicated QTc study of NORTHERA (droxidopa), an...
Chelsea Therapeutics Announces New Data from Northera Phase III Program in Neurogenic Orthostatic Hypotension Presented at MDS 15th International Congress of Parkinson's Disease and Movement Disorders
09 juin 2011 16h15 HE
|
Chelsea Therapeutics
Northera Treatment Provides Durable Beneficial Effects on both Systolic Blood Pressure and the Symptoms of NOH in Patients with Multiple System Atrophy
Robust Symptomatic Benefit of Northera...
Chelsea Therapeutics Reports First Quarter 2011 Results
09 mai 2011 16h05 HE
|
Chelsea Therapeutics
Preparing to File Northera New Drug Application in Third Quarter 2011
Opening Enrollment into High Dose Arms of Phase II Trial of CH-405 for Treatment of Rheumatoid Arthritis and On Track to...
Chelsea Therapeutics Announces Approval to Open Enrollment Into 3.0 mg Arms of CH-4051 Phase II Trial in Rheumatoid Arthritis
09 mai 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., May 9, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that an independent Data Safety Monitoring Board (DSMB) recently met to review patient...
Chelsea Therapeutics Announces Northera Poster Presentations and Symposium on Neurogenic Orthostatic Hypotension at MDS 15th International Congress of Parkinson's Disease and Movement Disorders
02 mai 2011 07h30 HE
|
Chelsea Therapeutics
Dr. Robert Hauser to Present Late Breaking Poster Highlighting Efficacy of Northera in Patients with Neurogenic Orthostatic Hypotension associated with Parkinson's Disease on June 8th...
Chelsea Therapeutics to Host Conference Call to Discuss First Quarter 2011 Results
28 avr. 2011 07h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., April 28, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release first quarter results for the period ended March 31, 2011...
Chelsea Therapeutics to Present at 36th Annual Deutsche Bank Healthcare Conference
27 avr. 2011 07h30 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., April 27, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 36th Annual Deutsche Bank Healthcare Conference at 2:50 PM ET...
Chelsea Therapeutics Confirms Plan to File Northera NDA for the Treatment of Neurogenic Orthostatic Hypotension in Third Quarter 2011 and Intent to Pursue Supplemental Falls Claim Following Approval
18 avr. 2011 08h00 HE
|
Chelsea Therapeutics
FDA Informs Chelsea that Data from 306 Studies Should Not be Included as Efficacy Data in NDA
FDA Confirms Reduction of Falls Endpoint in Study 306B Acceptable and Recommends Additional...
Chelsea Therapeutics to Present at 10th Annual Needham Healthcare Conference
05 avr. 2011 08h00 HE
|
Chelsea Therapeutics
CHARLOTTE, N.C., April 5, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 10th Annual Needham Healthcare Conference at 2:00 PM ET on...